Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as an anti-infective drug development company

Aviragen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.

The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV).

In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV).

Aviragen Therapeutics was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Managers
NameAgeSinceTitle
Joseph M. Patti, PhD522012President, Chief Executive Officer & Director
Russell H. Plumb MBA, CPA572012Executive Chairman
Mark P. Colonnese MBA, CPA602015Chief Financial Officer & Executive Vice President
Anna Novotney-Barry-2013Vice President-Clinical Development
John H. Vernachio, PhD-2014Vice President-Preclinical Development
Geoffrey F. Cox, PhD722012Independent Non-Executive Director
Anne M. VanLent682013Lead Director
Michael R. Dougherty582013Independent Non-Executive Director
John P. Richard, MBA592013Independent Non-Executive Director
Armando Anido, MBA582015Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 38,640,487 34,782,942 90.0% 0 0.0% 90.0%
Shareholders
NameEquities%
Broadfin Capital LLC 3,486,711 9.02%
East Hill Management Co. LLC 3,456,520 8.95%
Krensavage Asset Management LLC 2,708,438 7.01%
Senzar Asset Management LLC 2,034,576 5.27%
The Vanguard Group, Inc. 1,044,243 2.70%
BlackRock Fund Advisors 595,971 1.54%
Renaissance Technologies LLC 571,805 1.48%
Landon Thomas Clay 327,672 0.85%
Fidelity Management & Research Co. 300,000 0.78%
Stonepine Capital Management LLC 294,269 0.76%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
BIOTA PHARMACEUTICALS ..52
AMGEN, INC.5.19%127 790
GILEAD SCIENCES, INC.-23.00%102 828
CELGENE CORPORATION-10.64%82 953
REGENERON PHARMACEUTIC..-27.20%41 614
VERTEX PHARMACEUTICALS..-23.87%23 737
ACTELION LTD17.62%18 198
MEDIVATION INC66.24%13 334
GENMAB A/S18.26%9 868
HUALAN BIOLOGICAL ENGI..--.--%5 488
TONGHUA DONGBAO PHARMA..-83.39%4 821
TESARO INC64.55%4 422
NEUROCRINE BIOSCIENCES..-13.08%4 266
INTERCEPT PHARMACEUTIC..0.88%3 726
JUNO THERAPEUTICS INC-28.29%3 335
BEIJING SL PHARMACEUTI..--.--%3 235
CHINA BIOLOGIC PRODUCT..-22.08%2 985
KITE PHARMA INC-4.72%2 912
BIOCON LTD71.94%2 723
ULTRAGENYX PHARMACEUTI..-40.44%2 635
EXELIXIS, INC.95.74%2 543
Sector Bio Therapeutic Drugs
Biota Pharmaceuticals Inc : Connections
Beacon Street Advisors LLC
International AIDS Vaccine Initiative, Inc.
Massachusetts Biotechnology Council
Georgia Venture Partners LLC
Phase4 Partners Ltd.
Axotect, Inc.
Altiris Therapeutics, Inc.
QUE Oncology, Inc.
Altherx, Inc.
Zygogen LLC
Shire ViroPharma, Inc.
Lakewood-Amedex, Inc.
AMV Advisors
SciStem Therapeutics, Inc.
Cempra Pharmaceuticals, Inc.
Company contact information
Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web : www.aviragen.com
© 2016 People , Fundamentals and Ownership